The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being – An Early Review
Bornemann, J. | Journal of Psychoactive Drugs | 2 May 2020
Registered Clinical Trials Investigating Ketamine for Psychiatric Disorders
Peyrovian, B., McIntyre, R., Phan, L., Lui, L. M., Gill, H., Majeed, A., ... & Rosenblat, J. D. | Journal of Psychiatric Research | 9 April 2020
Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
Heuschkel, K., & Kuypers, K. P. | Frontiers in Psychiatry | 31 March 2020
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. | Neuroscience & Biobehavioral Reviews | 15 March 2020
Reviewing the Potential of Psychedelics for the Treatment of PTSD.
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. | International Journal of Neuropsychopharmacology | 14 March 2020
Psilocybin Therapeutic Research: The Present and Future Paradigm
Kargbo, R. B. | ACS Medicinal Chemistry Letters | 2 March 2020
Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder
Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., ... & Feduccia, A. A. | Journal of Traumatic Stress | 19 February 2020
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
Chi, T., & Gold, J. A. | Journal of the Neurological Sciences | 30 January 2020
In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation.
Berquist, M. D., Leth-Petersen, S., Kristensen, J. L., & Fantegrossi, W. E. | Drug and Alcohol Dependence | 13 January 2020
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., ... & Ross, S. | Journal of Psychopharmacology | 9 January 2020
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. | Psychiatry Research | 2 January 2020
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.
Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., & de Wit, H. | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging | 20 December 2019
From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner.
Kettner, H., Gandy, S., Haijen, E. C., & Carhart-Harris, R. L. | International Journal of Environmental Research and Public Health | 16 December 2019
Neurotrophic mechanisms of psychedelic therapy
Corne, R., & Mongeau, R. | Biologie aujourd'hui | 12 December 2019
Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
dos Santos, R. G., & Hallak, J. E. C. | Neuroscience & Biobehavioral Reviews | 3 December 2019
Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. | Psychopharmacology | 29 November 2019
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Lea, T., Amada, N., Jungaberle, H., Schecke, H., & Klein, M. | International Journal of Drug Policy | 25 November 2019
Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., ... & Liechti, M. E. | Neuropsychopharmacology | 16 November 2019
High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans.
Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. | Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists | 1 November 2019
Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. | BMC psychiatry | 28 October 2019
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers
Hutten, N. R., Mason, N. L., Dolder, P. C., & Kuypers, K. P. | Frontiers in psychiatry | 13 September 2019
The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
O’Brien, B., Lijffijt, M., Wells, A., Swann, A. C., & Mathew, S. J. | Pharmaceuticals | 11 September 2019
Hallucinogens and Their Therapeutic Use: A Literature Review
BEGOLA, M. J., & SCHILLERSTROM, J. E. | Journal of Psychiatric Practice | September 2019
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Sartori, S. B., & Singewald, N. | Pharmacology & therapeutics | 27 August 2019
MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment.
Vermetten, E., & Yehuda, R. | Neuropsychopharmacology | 27 August 2019